Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 1, 2021, Akebia Therapeutics, Inc. (the "Company") filed a Current Report on Form 8-K (the "Initial 8-K") disclosing that on and effective November 1, 2021, the Board of Directors of the Company (the "Board") increased the Board's size from eight to nine directors and elected Ron Frieson as a Class I director. At the time of filing the Initial 8-K, the Board had not made a determination regarding any committee assignments for Mr. Frieson.

This Current Report on Form 8-K/A amends the Initial 8-K to disclose that on and effective December 10, 2021, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the "NCG Committee"), the Board increased the size of the NCG Committee from three members to four members and appointed Mr. Frieson as a member of the NCG Committee.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses